Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Aibios
AddedFeb 13, 2024
UpdatedJun 18, 2026
Aibios

Aibios

Public

AIBIOS: Biotech innovator developing novel molecules to treat immune-related diseases.

HQ
Irvine, CA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to revolutionize the treatment of immune-related diseases, AIBIOS is a biotech company dedicated to developing novel small molecules that modulate both the innate and adaptive immune systems. The company focuses on therapeutic indications in Gastroenterology, Respiratory, and Neurological diseases. AIBIOS aims to address unmet medical needs and improve patient outcomes through continuous innovation and strategic partnerships.

AIBIOS has garnered attention for its cutting-edge research and development, attracting notable investors and collaborators in the biotech industry. The company's achievements include the successful design and development of several promising small molecules, positioning it as a leader in immune system modulation. Through its relentless pursuit of innovation, AIBIOS is making significant strides in improving treatment expectations for patients with inflammatory bowel disease (IBD) and other immune-related conditions, thereby shaping the future of disease management.

Aibios - Similar Companies

HI-Bio logo

HI-Bio

hibio.com

BridGene Biosciences logo

BridGene Biosciences

Precision IBD logo

Precision IBD

ABio-X logo

ABio-X

abio-x.com

Ibex Biosciences logo

Ibex Biosciences

ibex.bio

iBio logo

iBio

ibioinc.com

Invea Therapeutics logo

Invea Therapeutics

inveatx.com

Brii Biosciences logo

Brii Biosciences

briibio.com

Modulo Bio logo

Modulo Bio

modulo.bio

IpiNovyx Bio logo

IpiNovyx Bio

BioHealthonomics logo

BioHealthonomics

Imidomics logo

Imidomics

imidomics.com

Aria Pharmaceuticals logo

Aria Pharmaceuticals

Aiko Biotechnology logo

Aiko Biotechnology

BioAI Health logo

BioAI Health

bioaihealth.com

Aibios - Quick Facts

Who are Aibios' competitors?

Companies similar to Aibios include HI-Bio, BridGene Biosciences, Precision IBD and ABio-X.

When was Aibios founded?

Aibios was founded in 2018.

Where is Aibios' headquarters located?

Aibios' headquarters is located in Irvine, CA, US.

When was Aibios' last funding round?

Aibios' most recent funding round was for $500M (USD) in April 2021.

How much has Aibios raised to-date?

As of Apr 28, 2021, Aibios has raised a total of $850M (USD).

How many employees does Aibios have?

Aibios has 6 employees as of Feb 4, 2024.

Aibios - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Biotech
  • Pharmaceuticals
Tags
  • Biotech
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software